Page last updated: 2024-09-03

salvinorin a and beta-funaltrexamine

salvinorin a has been researched along with beta-funaltrexamine in 1 studies

Compound Research Comparison

Studies
(salvinorin a)
Trials
(salvinorin a)
Recent Studies (post-2010)
(salvinorin a)
Studies
(beta-funaltrexamine)
Trials
(beta-funaltrexamine)
Recent Studies (post-2010) (beta-funaltrexamine)
2477128542154

Protein Interaction Comparison

ProteinTaxonomysalvinorin a (IC50)beta-funaltrexamine (IC50)
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)0.082
Prostaglandin G/H synthase 1Homo sapiens (human)0.082
Delta-type opioid receptorMus musculus (house mouse)0.082
Kappa-type opioid receptorMus musculus (house mouse)0.082
Mu-type opioid receptorMus musculus (house mouse)0.082

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Do Rego, JC; Fichna, J; Grzywacz, D; Kamysz, W; Polepally, PR; SaƂaga, M; Sibaev, A; Sobczak, M; Storr, M; Zjawiony, JK1

Other Studies

1 other study(ies) available for salvinorin a and beta-funaltrexamine

ArticleYear
Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
    The Journal of pharmacology and experimental therapeutics, 2014, Volume: 350, Issue:1

    Topics: Abdominal Pain; Administration, Oral; Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Diarrhea; Disease Models, Animal; Diterpenes, Clerodane; Dose-Response Relationship, Drug; Exploratory Behavior; Gastrointestinal Motility; Injections, Intraperitoneal; Irritable Bowel Syndrome; Male; Mice; Motor Activity; Naltrexone; Receptors, Opioid, kappa; Receptors, Opioid, mu

2014